Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine

Adjuvance Technologies, Inc., New York NY

Investigators

Abstract

Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenic, requiring use of an immunological adjuvant for best effect. Adjuvance's semi-synthetic saponin adjuvant TiterQuil-1055 (TQL1055) has demonstrated efficacy with a variety of antigens with no detectable reactogenicity. The objectives of the Phase I project are to test whether TQL1055 can enhance the immunogenicity and efficacy of influenza vaccines, and to conduct IND enabling stability studies.